IMed Consultancy Limited

Activities: Regulatory

Trending Articles

  1. Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
  2. Therapeutic: ensifentrine for chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
  3. Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
  4. Bringing biotech to the Baltics: the rise of Lithuania Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
  5. Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA

Upcoming event

ISPE Singapore

28-30 August 2024 | Conference and exhibition | Singapore See all

Related Content

Pharma 5.0

Unlocking potential through regulation: the AI revolution in medical devices

The healthcare industry is entering a transformative era with the emergence of digital technologies. Innovations such as wearable sensors to monitor vital signs and AI-powered diagnostic tools are poised to revolutionise healthcare delivery. However, navigating the evolving regulatory landscape remains a significant challenge
Regulatory

IMed launches new whitepaper exploring regulatory challenges for AI and ML in medical devices and digital health products

IMed Consultancy shares free paper assessing the regulatory state of play for artificial intelligence (AI) and machine learning (ML)-powered medical devices in the UK, US and EU
Regulatory

The key role of IVDs in healthcare: challenges to commercialisation and access

In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
Regulatory

The entry conundrum for every medical device: which market first?

Regulatory bodies around the world are tackling the concerns raised by new technologies as well as seeking ways to accelerate the opportunities they provide to support patients, reports Leeanne Baker, Managing Director and Senior QA/RA Consultant at IMed Consultancy
Regulatory

Unlocking opportunities: entering the UK medical device market successfully

In the changing landscape of European medical device regulations, the UK remains an attractive destination for US and foreign businesses. Unlike the European Union (EU), the UK continues to operate within its consolidated regulatory framework, thereby positioning itself as an ideal market for novel and niche products
Subscribe now